Track topics on Twitter Track topics that are important to you
Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become ...
The post Cambridge Company Raises €20M for Potential First in Lung Disease appeared first on Labiotech.eu.
Original Article: Cambridge Company Raises €20M for Potential First in Lung DiseaseNEXT ARTICLE